Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.34 USD | +0.49% | -16.30% | +34.39% |
02:26pm | Immunome, Inc. Appoints Sandra M. Swain to Board of Directors | CI |
Apr. 15 | Guggenheim Starts Immunome With Buy Rating, $35 Price Target | MT |
Financials (USD)
Sales 2024 * | 8M | Sales 2025 * | - | Capitalization | 852M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -149M | EV / Sales 2024 * | 106 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.14
x | P/E ratio 2025 * |
-6.01
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
1 day | +0.63% | ||
1 week | -16.18% | ||
Current month | -41.65% | ||
1 month | -40.00% | ||
3 months | -12.20% | ||
6 months | +61.43% | ||
Current year | +34.58% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 14.36 | +0.63% | 351 414 |
24-04-24 | 14.27 | -2.66% | 555,483 |
24-04-23 | 14.66 | -4.06% | 891,857 |
24-04-22 | 15.28 | -1.29% | 1,315,586 |
24-04-19 | 15.48 | -9.90% | 2,102,548 |
Delayed Quote Nasdaq, April 25, 2024 at 10:26 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.58% | 852M | |
-3.01% | 104B | |
+0.63% | 97.42B | |
+1.28% | 22.2B | |
-18.03% | 21.23B | |
-10.51% | 18.33B | |
-42.33% | 16.35B | |
-17.89% | 15.06B | |
+4.84% | 13.98B | |
+28.19% | 11.66B |
- Stock Market
- Equities
- IMNM Stock